


THE XLP RESEARCH TRUST SYMPOSIUM 2018

A Symposium for
Researchers and Clinicians on
XLP1 and XIAP

5th BI-ANNUAL



London
29th October
2018

Update on Agenda @ 19th July 2018

We are pleased to confirm that at this moment we have 12 papers that we have received and have been accepted, 6 for XLP1 and 6 for XIAP.

Our speakers are coming from across the world including: France, Italy, Japan, Switzerland, UK & USA.

Titles include:

XLP1

- Developing novel T cell therapies for XLP1
- TALEN-mediated genome editing via AAV6 donor in T cells for the treatment of X-linked lymphoproliferative disease (XLP)
- Modification of cellular and humoral immunity by somatically reverted T cells in XLP1
- Novel DGKa Inhibitors for XLP1 therapy via virtual screening
- Diacylglycerol kinase- α is an effector of SASP/NCK1/WASP/cdc42-GTP signalling regulating cytoskeleton remodelling and Restimulation Cell Death
- CD8 defects in XLP1 and Activated P13 Kinase Syndrome

XIAP

- An update on outcome following Haematopoietic stem cell transplantation in XIAP deficiency
- XIAP deficiency and inflammatory bowel disease
- Dysregulated IL 1-beta secretion in XIAP deficiency is abrogated by the natural flavonoid quercetin
- Correction of innate immune responses in XIAP deficiency using egen modified haematopoietic stem cells
- Determining anti-viral immune responses and cell death pathways in XIAP deficiencies
- Critical role of T-cell expansion in immunity to EBV revealed by genetic defects with high predisposition to EBV infection

The full agenda will be released shortly

We'd again like to thank the Jeffrey Modell Foundation for awarding is a WIN grant to reduce the cost of the symposium.

